Table 2.
Summary of phosphatidylinositol-3 kinases/Akt/mTOR inhibitors under investigation for gastric cancer treatment
| Classification of PI3K/Akt/mTOR inhibitors | Inhibitors under investigation for GC | Clinical status for GC |
| PI3K inhibitors: 3 classes of PI3K inhibitors | ||
| Pan-class I inhibitors | PX-866 | Phase-II study for solid tumors |
| NVP-BKM120 | Phase-I study for advanced solid tumors | |
| ZSTK474 | Preclinical studies | |
| BAY80-6946 | Phase-II study for advanced solid tumors | |
| Isoform specific PI3K inhibitors | BYL719 | Phase-I study |
| INK117 | Phase-I study | |
| Dual Akt/mTOR inhibitors | NVP-BEZ235 | Preclinical studies |
| VS-5884 | Phase-II study | |
| PI-103 | Phase-I study | |
| Akt inhibitors | AZD5363 | Preclinical studies |
| MK-2206 | Phase-II study | |
| Perifosine | Preclinical studies | |
| TCN-PM | Phase-I study for solid tumors | |
| mTOR inhibitors: 2 types | ||
| Rapalogs | Everolimus | Phase-III study |
| Ridaforolims | Preclinical studies | |
| Sirolimus | Phase-I study | |
| Temsirolimus | Phase-II study | |
| mTORC1/2 inhibitors | PP242 | Preclinical studies |
GC: Gastric cancer; PI3K: Phosphatidylinositol-3 kinases.